Procyon Advisors LLC Acquires 3,842 Shares of AstraZeneca PLC (NASDAQ:AZN)

Procyon Advisors LLC boosted its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 12.9% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 33,695 shares of the company’s stock after buying an additional 3,842 shares during the period. Procyon Advisors LLC’s holdings in AstraZeneca were worth $2,208,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the stock. Stratos Wealth Advisors LLC boosted its holdings in AstraZeneca by 2.0% during the third quarter. Stratos Wealth Advisors LLC now owns 6,699 shares of the company’s stock worth $522,000 after purchasing an additional 133 shares during the last quarter. Crumly & Associates Inc. boosted its stake in shares of AstraZeneca by 2.2% during the 3rd quarter. Crumly & Associates Inc. now owns 6,644 shares of the company’s stock worth $518,000 after buying an additional 143 shares during the last quarter. Harbour Investments Inc. grew its holdings in shares of AstraZeneca by 1.9% in the 3rd quarter. Harbour Investments Inc. now owns 8,805 shares of the company’s stock valued at $686,000 after acquiring an additional 160 shares in the last quarter. Smith Salley Wealth Management increased its position in shares of AstraZeneca by 1.0% in the third quarter. Smith Salley Wealth Management now owns 16,158 shares of the company’s stock valued at $1,259,000 after acquiring an additional 162 shares during the last quarter. Finally, Veracity Capital LLC raised its holdings in AstraZeneca by 4.5% during the third quarter. Veracity Capital LLC now owns 3,833 shares of the company’s stock worth $299,000 after acquiring an additional 164 shares in the last quarter. Institutional investors own 20.35% of the company’s stock.

AstraZeneca Stock Down 0.5 %

AZN stock opened at $66.60 on Friday. The business’s 50 day simple moving average is $66.06 and its 200 day simple moving average is $74.57. AstraZeneca PLC has a 1-year low of $60.47 and a 1-year high of $87.68. The firm has a market capitalization of $206.50 billion, a PE ratio of 31.87, a PEG ratio of 1.05 and a beta of 0.46. The company has a current ratio of 0.93, a quick ratio of 0.71 and a debt-to-equity ratio of 0.71.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, beating the consensus estimate of $1.01 by $0.03. The firm had revenue of $13.57 billion for the quarter, compared to the consensus estimate of $13.08 billion. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The company’s quarterly revenue was up 18.0% on a year-over-year basis. During the same period in the previous year, the company earned $0.87 earnings per share. As a group, research analysts anticipate that AstraZeneca PLC will post 4.11 EPS for the current year.

Analyst Ratings Changes

Several research analysts have weighed in on the company. UBS Group raised AstraZeneca from a “sell” rating to a “neutral” rating in a research report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, AstraZeneca presently has a consensus rating of “Buy” and a consensus price target of $89.75.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.